



Please complete ALL information below and fax your request to 1-888-671-5285

Simponi® & Simponi Aria® Prior Authorization Request Form (Page 1 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:
Medication Information (required)					
Medication Name:			Strength:	Dosage Form:	
<input type="checkbox"/> Check if generic substitution is acceptable			Directions for Use:		
<input type="checkbox"/> Check if request is for continuation of therapy					
Clinical Information (required)					
Select the diagnosis below:					
<input type="checkbox"/> Ankylosing spondylitis (for example: M45.0, M45.9)					
<input type="checkbox"/> Psoriatic arthritis (for example: arthropathic psoriasis; L40.5, L40.59)					
<input type="checkbox"/> Rheumatoid arthritis (for example: M05.79, M06.9)					
<input type="checkbox"/> Ulcerative colitis (for example: ulcerative pancolitis; K51.00, K51.90, K51.919)					
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____					
Clinical Information:					
Select if Simponi or Simponi Aria is prescribed by or in consultation with one of the following specialists:					
<input type="checkbox"/> Dermatologist <input type="checkbox"/> Gastroenterologist <input type="checkbox"/> Rheumatologist					
Is the patient receiving Simponi or Simponi Aria in combination with a biologic DMARD (e.g., Enbrel [etanercept], Humira [adalimumab], Cimzia [certolizumab], Orencia [abatacept])? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Ankylosing Spondylitis:					
Does the patient have active disease? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Has the patient had a trial and failure, contraindication, or intolerance to two non-steroidal anti-inflammatory drugs (NSAIDs)? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Psoriatic Arthritis:					
Does the patient have active disease? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Rheumatoid Arthritis:					
Does the patient have moderately to severely active disease? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Is the patient receiving concurrent therapy with methotrexate (Rheumatrex, Trexall)? <input type="checkbox"/> Yes <input type="checkbox"/> No					
If "no" to the above, has the patient had a trial and failure, contraindication, or intolerance to methotrexate (Rheumatrex, Trexall)? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Ulcerative Colitis:					
Does the patient have moderately to severely active disease? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Is the patient corticosteroid dependent (i.e., an inability to successfully taper corticosteroids without a return of the symptoms of ulcerative colitis)? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Select if the patient has had a trial and failure, contraindication, or intolerance to the following conventional therapies:					
<input type="checkbox"/> 6-mercaptopurine (Purinethol)					
<input type="checkbox"/> Aminosalicylate (e.g., mesalamine [Asacol, Pentasa, Rowasa], olsalazine [Dipentum], sulfasalazine [Azulfidine, Sulfazine])					
<input type="checkbox"/> Azathioprine (Imuran)					
<input type="checkbox"/> Corticosteroids (e.g., prednisone, methylprednisolone)					

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of FutureScripts. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. If you are not the intended recipient, please notify the sender immediately.

Office use only: Simponi-SimponiAria_FSP_2019Apr-W



Simponi® & Simponi Aria® Prior Authorization Request Form (Page 2 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Reauthorization:

Is there documentation the patient has had a positive clinical response to therapy? Yes No

Is the patient receiving Simponi or Simponi Aria in combination with a biologic DMARD (e.g., Enbrel [etanercept], Humira [adalimumab], Cimzia [certolizumab], Orencia [abatacept])? Yes No

Quantity Limit Requests:

What is the quantity requested per DAY? _____

What is the reason for exceeding the plan limitations?

- Titration or loading dose purposes
- Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)
- Requested strength/dose is not commercially available
- Other: _____

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.